185 related articles for article (PubMed ID: 35691603)
1. Comparative efficacy and safety of systemic antifungal agents for candidemia: a systematic review with network meta-analysis and multicriteria acceptability analyses.
Domingos EL; Vilhena RO; Santos JMMF; Fachi MM; Böger B; Adam LM; Tonin FS; Pontarolo R
Int J Antimicrob Agents; 2022 Aug; 60(2):106614. PubMed ID: 35691603
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of micafungin in invasive candidiasis caused by common Candida species with special emphasis on non-albicans Candida species.
Cornely OA; Vazquez J; De Waele J; Betts R; Rotstein C; Nucci M; Pappas PG; Ullmann AJ
Mycoses; 2014 Feb; 57(2):79-89. PubMed ID: 23786573
[TBL] [Abstract][Full Text] [Related]
3. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and Safety of Echinocandins for the Treatment of Invasive Candidiasis in Children: A Meta-analysis.
Tsekoura M; Ioannidou M; Pana ZD; Haidich AB; Antachopoulos C; Iosifidis E; Kolios G; Roilides E
Pediatr Infect Dis J; 2019 Jan; 38(1):42-49. PubMed ID: 29596219
[TBL] [Abstract][Full Text] [Related]
5. Cost-utility analysis of caspofungin and fluconazole for primary treatment of invasive candidiasis and candidemia in Ethiopia.
Gebretekle GB; Fentie AM; Gebremariam GT; Ali EE; Erku DA; Alemayehu T; Abebe W; Sander B
BMC Health Serv Res; 2022 Oct; 22(1):1302. PubMed ID: 36309674
[TBL] [Abstract][Full Text] [Related]
6. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature.
Wilke M
Eur J Med Res; 2011 Apr; 16(4):180-6. PubMed ID: 21486732
[TBL] [Abstract][Full Text] [Related]
7. Comparative effectiveness of amphotericin B, azoles and echinocandins in the treatment of candidemia and invasive candidiasis: A systematic review and network meta-analysis.
Demir KK; Butler-Laporte G; Del Corpo O; Ekmekjian T; Sheppard DC; Lee TC; Cheng MP
Mycoses; 2021 Sep; 64(9):1098-1110. PubMed ID: 33894072
[TBL] [Abstract][Full Text] [Related]
8. Risk factors of mortality and comparative in-vitro efficacy of anidulafungin, caspofungin, and micafungin for candidemia.
Lee SC; Lee CW; Shih HJ; Huang SH; Chiou MJ; See LC
J Microbiol Immunol Infect; 2014 Jun; 47(3):245-53. PubMed ID: 24246191
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of rezafungin and caspofungin in candidaemia and invasive candidiasis: pooled data from two prospective randomised controlled trials.
Thompson GR; Soriano A; Honore PM; Bassetti M; Cornely OA; Kollef M; Kullberg BJ; Pullman J; Hites M; Fortún J; Horcajada JP; Kotanidou A; Das AF; Sandison T; Aram JA; Vazquez JA; Pappas PG
Lancet Infect Dis; 2024 Mar; 24(3):319-328. PubMed ID: 38008099
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and tolerability of micafungin monotherapy for candidemia and deep-seated candidiasis in adults with cancer.
Farmakiotis D; Tarrand JJ; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Jun; 58(6):3526-9. PubMed ID: 24637687
[TBL] [Abstract][Full Text] [Related]
11. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
Glöckner A
Eur J Med Res; 2011 Apr; 16(4):167-79. PubMed ID: 21486731
[TBL] [Abstract][Full Text] [Related]
12. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
Moen MD; Lyseng-Williamson KA; Scott LJ
Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
[TBL] [Abstract][Full Text] [Related]
13. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.
Neoh CF; Senol E; Kara A; Dinleyici EC; Turner SJ; Kong DCM
Eur J Clin Microbiol Infect Dis; 2018 Mar; 37(3):537-544. PubMed ID: 29185089
[TBL] [Abstract][Full Text] [Related]
16. Economic evaluation of micafungin versus caspofungin for the treatment of candidaemia and invasive candidiasis.
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Intern Med J; 2013 Jun; 43(6):668-77. PubMed ID: 23461421
[TBL] [Abstract][Full Text] [Related]
17. Treatment of invasive candidal infections: systematic review and meta-analysis.
Gafter-Gvili A; Vidal L; Goldberg E; Leibovici L; Paul M
Mayo Clin Proc; 2008 Sep; 83(9):1011-21. PubMed ID: 18775201
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of micafungin vs. liposomal amphotericin B (LAmB) for the treatment of candidaemia and invasive candidiasis (IC).
Neoh CF; Liew D; Slavin MA; Marriott D; Chen SC; Morrissey O; Stewart K; Kong DC
Mycoses; 2013 Sep; 56(5):532-42. PubMed ID: 23496163
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis.
Kubiak DW; Bryar JM; McDonnell AM; Delgado-Flores JO; Mui E; Baden LR; Marty FM
Clin Ther; 2010 Apr; 32(4):637-48. PubMed ID: 20435233
[TBL] [Abstract][Full Text] [Related]
20. Echinocandin use in the neonatal intensive care unit.
Caudle KE; Inger AG; Butler DR; Rogers PD
Ann Pharmacother; 2012 Jan; 46(1):108-16. PubMed ID: 22190252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]